INTRODUCTION
Chemical peels are a popular, effective, noninvasive and relatively safe modality to improve skin appearance and to treat various skin problems, such as acne, pigmentation, scars, wrinkles, melasma, and photoaging among others. They are categorized according to their depth of penetration into superficial, medium, and deep peels.1,2 Peels are commonly used in clinical settings and found in many cosmetic products.1,3
Glycolic acid (GA) is a commonly used superficial peel with higher concentrations and lower pH levels leading to a stronger effect despite a higher risk of adverse effects. Most common adverse effects following glycolic acid peel are the sensation of burning, pain or itching, erythema, and edema.1,3-5 A novel protective complex (NOON Aesthetics®, Tel Aviv, IL), known as the DermShield™, was developed to be added to the peel in order to allow the use of high concentration GA peel at a low pH, while reducing the accompanying negative adverse effects on the skin. The purpose of this study is to examine this novel protective complex (NPC) for its anti-irritation effect, tolerability, efficacy, and safety while added to the GA 50% peel.
Glycolic acid (GA) is a commonly used superficial peel with higher concentrations and lower pH levels leading to a stronger effect despite a higher risk of adverse effects. Most common adverse effects following glycolic acid peel are the sensation of burning, pain or itching, erythema, and edema.1,3-5 A novel protective complex (NOON Aesthetics®, Tel Aviv, IL), known as the DermShield™, was developed to be added to the peel in order to allow the use of high concentration GA peel at a low pH, while reducing the accompanying negative adverse effects on the skin. The purpose of this study is to examine this novel protective complex (NPC) for its anti-irritation effect, tolerability, efficacy, and safety while added to the GA 50% peel.
MATERIALS AND METHODS
This prospective, double blind, split-face controlled study aimed to evaluate the potential of the NPC to reduce facial adverse effects following a GA chemical peel treatment. The clinical trial was carried out at an outpatient private clinic in the period from January 2019 till March 2019. After approval of the Institutional Review Board (IRB), informed consent was obtained from all subjects prior to beginning the study.
One month prior to the trial, all patients could apply only a moisturizer and a sunscreen. A pair of numbered kits were supplied by NOON Aesthetics and assigned to each patient. The company used a designated software to randomize the patient number, facial halves, and the treated (50% GA peel plus NPC) Vs. the control formulations (only 50% GA peel). The two kits were identical in shape, size, and weight, as well as color, odor, and consistency. A randomized list was kept away to ensure the integrity of the trial. Neither the treating physician nor the patients knew which facial half was treated by the study or control kit.
Demographics, including age, medical history, dermatological
One month prior to the trial, all patients could apply only a moisturizer and a sunscreen. A pair of numbered kits were supplied by NOON Aesthetics and assigned to each patient. The company used a designated software to randomize the patient number, facial halves, and the treated (50% GA peel plus NPC) Vs. the control formulations (only 50% GA peel). The two kits were identical in shape, size, and weight, as well as color, odor, and consistency. A randomized list was kept away to ensure the integrity of the trial. Neither the treating physician nor the patients knew which facial half was treated by the study or control kit.
Demographics, including age, medical history, dermatological
